Tandem Diabetes Care, Inc. (TNDM) Stock Analysis

Company Overview

Tandem Diabetes Care, Inc. (TNDM) is capitalised at $1.38B on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 2,500.

TNDM last closed at $19.90 on September 4, 2026. That is −$0.53 (−2.59%) against the previous close. Over the past 52 weeks the price has ranged from $11.46 to $29.65. The latest close sits 73.65% above that 52-week low.

Financial Health

In fiscal 2025, Tandem Diabetes Care, Inc. reported revenue of $1.01B. That is +7.93% against the prior fiscal year, when revenue was $940.20M. The same year closed with a net loss of $204.71M. Profit margin runs at −6.08%. That is 4.4 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.9.

Across the 4 fiscal years on file, revenue moves from $801.22M in 2022 to $1.01B in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 116.58. Measured against sales, the shares trade at 1.33 times revenue. On price-to-sales that is 55.33% below the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.56. Daily returns over the trailing 10 years annualize to a volatility of 78.04%. The trailing one-year price return is +60.61%. Across 10 years the annualized return works out at −11.89%.

Growth & Income

The record shows no dividend for TNDM.

Across the complete calendar years on file, 2018 returned +1,508.90% and 2017 returned −89.02%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −9.46% year to date.